X0306 4 2017-11-28 0 0001095981 CYTORI THERAPEUTICS, INC. CTYX 0001655866 HARRIS JOHN DAVID 3020 CALLAN ROAD SAN DIEGO CA 92121 0 1 0 0 VP and GM Cell Therapy Subscription Rights (Right to Buy) 1000.00 2017-11-28 4 X 0 1 D 2017-11-02 2017-11-21 see footnote 0 D Series B Preferred Stock 0.3333 2017-11-28 4 X 0 1 A 2017-11-28 Common Stock 3000 1 D Warrants (Right to Buy) 0.3333 2017-11-28 4 X 0 1800 A 2020-05-28 Common Stock 1800 1800 D The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. The Series B Preferred Stock has no expiration date. Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.3333 per share from the date the Company receives stockholder approval of an amendment to its certificate of incorporation to increase its authorized shares of common stock through May 28, 2020. Tiago Girao, By Power of Attorney For: John David Harris 2017-11-29